Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.

Kohei ShitaraRui-Hua XuJaffer A AjaniDiarmuid MoranAbraham GuerreroRan LiJanet PaveseMaria MatsangouPranob BhattacharyaYoko UenoXuewei WangManish A Shah

Published in: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (2024)

CLDN18.2 was a highly prevalent biomarker in patients with HER2-negative, LA unresectable or mG/GEJ adenocarcinoma. CLDN18.2 positivity remained relatively stable over time in many patients. Biomarker testing for CLDN18.2 should be considered in standard clinical practice in these patients.

Keyphrases

locally advanced
squamous cell carcinoma
end stage renal disease
newly diagnosed
ejection fraction
rectal cancer
clinical practice
peritoneal dialysis
prognostic factors
small cell lung cancer
risk factors
radiation therapy
patient reported outcomes
clinical trial
lymph node
patient reported
open label